Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 5, 2023 Category: Pharmaceuticals Source Type: clinical trials
Everest Medicines Announces Investigational New Drug Application Acceptance of Zetomipzomib in China
SHANGHAI, Dec. 3, 2023. Everest Medicines ( " Everest " , or the " Company " ), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that China National Medical... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
SAN DIEGO December 4, 2023– Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Johnson & Johnson ’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
RARITAN, N.J., Dec. 4, 2023– Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD) for the potential future treatment of patients with Bacillus... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting
PIK3CA mutations, found in approximately 40% of HR-positive... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks
While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 1, 2023 Category: Pharmaceuticals Source Type: clinical trials
Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort
SYDNEY, Nov. 29, 2023. Clarity Pharmaceuticals ( " Clarity " ), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 30, 2023 Category: Pharmaceuticals Source Type: clinical trials
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
LUMINOSITY trial demonstrated compelling clinical benefits across key endpoints
Teliso-V is an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 29, 2023 Category: Pharmaceuticals Source Type: clinical trials
Merck ’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
The 21 serotypes covered by V116 are responsible for approximately 83% of invasive pneumococcal disease in individuals 65 years of age and older, according to CDC data from 2018-2021
Results from Phase 3 trial, STRIDE-3, to be presented at World... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced a clinical update regarding its proprietary anti-PSMA antibody drug conjugate (ADC) ARX517 in the ongoing APEX-01 Phase 1 / 2 dose... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
EDINBURGH, Scotland, Nov. 27, 2023. TC BioPharm (Holdings) PLC ( " TC BioPharm " or the " Company " ) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 28, 2023 Category: Pharmaceuticals Source Type: clinical trials
FDA Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection
TAIPEI, Nov. 21, 2023. Senhwa Biosciences, Inc., a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced today that U.S. Food and Drug Administration has approved its Phase... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 22, 2023 Category: Pharmaceuticals Source Type: clinical trials
Viriom's Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials
SAN DIEGO, Nov. 20, 2023. Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 21, 2023 Category: Pharmaceuticals Source Type: clinical trials
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
Leuven, BELGIUM, Boston, MA, US– November 20, 2023– 7:00 am CET– Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company announced today that topline data in its KALAHARI Phase 2, Part B clinical trial for diabetic... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 20, 2023 Category: Pharmaceuticals Source Type: clinical trials
